# **CCSS** Investigator Meeting

June 14, 2023



Childhood Cancer Survivor Study



An NCI-funded Resource

## Meeting Agenda Overview

Time (Central Time)	Presentation			
2:00 pm – 3:00 pm	Principal Investigator Report, Support Facility Reports			
3:40 pm – 4:00 pm	Break			
4:00 pm – 6:30 pm	Plenary Session			
6:30 pm – 7:30 pm	Founders Reception (Garden Courtyard)			
6:30 pm – 9:00 pm	6:30 pm – 7:30 pm			
Thursday, June 15				
7:00 am – 7:45 am	CCSS 101: Led by Eric Chow!			
8:00 am – 10:30 pm	Plenary Session: Working Group Chair Reports			
10:30 am – 11:30 am	Working Group Breakout Sessions			





# CCSS 101 is back!


An introduction to CCSS how to maximally leverage the resource for survivorship research

Thursday, June 15, 7:00-7:45 AM

Eric Chow, MD Co-Chair, Chronic Conditions Working Group



## Childhood Cancer Survivor Study (U24 CA 55727) Study Participants




#### **Resource for Survivorship Research**

- Multi-institutional (n=31)
- 38,036 eligible survivors
- Open resource
- Cited >26,500 times
- >1,225 Investigators
- 91 Early career trainees
- 66 Investigator-initiated studies
- >\$80 million investigator-initiated grant support
   Childhood Cancer

Childhood Cancer Survivor Study An NCI-funded resource

## Childhood Cancer Survivor Study (U24 CA55727)

- Funded in 1994
- Retrospective cohort, recent expansion includes survivors diagnosed 1970-1999
- 5-year survival
- Leukemia, lymphoma, CNS, bone, Wilms, NBL, soft-tissue and bone sarcoma
- Detailed treatment data
- Wide range of outcomes



CCSS

\* indicates expansion cohort population

# **CCSS** Principal Investigator Report

June 14, 2023



Childhood Cancer Survivor Study



An NCI-funded Resource

# Funding Years 28-32: Update

## Maintain and Promote the Resource

- Ongoing Follow-up of the active participants in the cohort (1970-1999)
- Support for Coordinating Center (St. Jude) and four support facilities for tracking/tracing, data cleaning/freeze, blood/tissue collection, SMN pathology confirmation, biorepository, and analysis/publication of results


CCSS

## Enhance the Resource

Major New Objectives:

- 1. Aging and Accelerated Aging
- 2. Health Services Research
- 3. Cloud-based Data Sharing / Data Analysis Ecosystem
- 4. Strategic Plan for Future Cohort Expansion

## CCSS Abstracts and Publications



## 2022-2023 CCSS Publications (n=39)

#### Impact Factor >10 (N=22)

Am J Hum Genet Blood J Clin Oncol JAMA Netw Open JAMA Oncol JNCI Lancet Lancet Oncol Nature Medicine

-54% in journals with impact factor >10 (vs. 26%, 2021)

## Impact Factor 5-10 (N=7)

**CCSS** 

Cancer JACC CardioOncol J Am Heart Assoc JCO Precis Oncol Transl Psychiatry

## Impact Factor <5 (N=10)

Biomed Phys Eng Express BMC Health Services Research BMC Open Cancer Epidemiol Biomarkers Prev Clin Orthop Relat Res J Cancer Surv PloS One

## CCSS Abstract Highlights

## 2023 to date:

## 29 unique abstracts submitted for presentation

ASCO (15 submitted: 1 oral, 2 poster discussion, 8 poster, 4 online only/withdrawn)

- Oral: Medicaid Enrollment Changes After Medicaid Expansion, Xu Ji, Emory University
- Poster Discussion:
  - Genetic Study of Type 2 Diabetes in Diverse Populations (SJLIFE/CCSS), Cindy Im/Yadav Sapkota

CCS

Predicting Therapy Induced Cardiomyopathy (SJLIFE/CCSS), Katyrina Petrykey/Yadav Sapkota

## CCSS Abstracts at ISLCCC

## Title

#### **Oral Presentation**

Genetic study of diabetes in diverse populations (SJLIFE) Treatment and toxicity after subsequent breast cancer Predicting breast cancer after HL (Dutch HL Surv. Study) Subsequent meningiomas Cumulative burden of major surgical intervention GWAS of doxorubicin induced cardiomyopathy (SJLIFE) Polygenic risk of anthracycline cardiomyopathy (COG) Cancer predisposition variants and late mortality (SJLIFE) Mortality and SMNs beyond age 50

Yadav Sapkota (SJCRH) Cindy Im (U. Minn.) Roberti Sander (Netherlands Ca. Inst.) Lucie Turcotte (U. Minn.) Andrew Murphy (SJCRH) Kateryna Petrykey (SJCRH) Noha Sharafeldin (UAB) Cheng Chen (SJCRH) Rusha Bhandari (City of Hope)

## **First Author**

## CCSS Abstracts at ISLCCC

#### **First Author**

#### **Rapid Oral Presentation**

Updated colorectal RT dosimetry Subsequent CNS malignancies Role of BAG3 and TTN in cardiomyopathy (SJLIFE) Injury-related late mortality

Title

Constance Owens (MDA) Robert Galvin (U. Minn.) Achal Neupane (SJCRH) Margaret Lubas (Radford)

## 7 Ongoing Intervention Trials (Ancillary Studies)



## Follow-Up 7 Survey: Completed!

<u>Goal</u>: Comprehensive Outcome Assessment of the Cohort (32 pages)

**CCSS** 

Status: Complete!

#### Data Freeze:

- Survey data freeze complete
- SMN, CTCAE graded health conditions, NDI data pending freeze
  - Final freeze anticipated by end of summer

Aging and Accelerated Aging

We will expand the collection of data to evaluate physiologic and neurocognitive function with aging, characterize accelerated aging, and investigate the underlying physiology of aging as survivors enter their 4<sup>th</sup> - 6<sup>th</sup> decades of life.

CCSS

1. PRO-based data collection, focused on functional outcomes

## Follow-up 8: New Measures for Aging

- 20 pages in length, Development Team: Ness, Krull, Snyder, Nathan, Leisenring, Alston, McDonald
- Field tested with minor concerns addressed
- Includes all new scales as we proposed in the competitive renewal

Attachment 4, Table 2: Proposed Patient Reported Outcomes for Assessment of Aging and Accelerated Aging in the Next Funding Period					
Name of Scale	Main Constructs Included				
PHYISCAL PERFORMANCE ASSESSMENT					
Katz Activities of Daily Living	Self-reported functional status including bathing, transferring, dressing, self-care tasks for independent living.				
Lawton Instrumental Activities of Daily Living	Self-reported functional status including using the telephone, transportation, housekeeping, ability to manage finances and prepare meals and other tasks required to live independently.				
Fried Frailty Criteria (Self-reported)	Identifies survivors with physiologic frailty				
Cumulative Illness Rating Scale	Summarizes disease burden across 14 organ-systems, with items scored 0-4 (none to extremely severe problem).				
NEUROCOGNITIVE ASSESSMENT					
CCSS Neurocognitive Questionnaire (NCQ)	Task efficiency (attention + processing speed), memory, executive function.				
PROMIS Cognitive Function SF	General cognitive function.				
PROMIS Social Roles and Activities SF	Social roles and community activities.				
Alzheimer's Disease Caregiver Questionnaire	Memory, language, executive function, behavior.				

## Follow-Up 8 Survey: CURRENT STATUS

CCSS

<u>Goal</u>: Assessment of aging functional outcomes (20 pages)

## <u>Status</u>:

- First e-only push, and first paper mail-out complete
- Anticipate completion of FU8 in 2024

Aging and Accelerated Aging

We will expand the collection of data to evaluate physiologic and neurocognitive function with aging, characterize accelerated aging, and investigate the underlying physiology of aging as survivors enter their 4<sup>th</sup> - 6<sup>th</sup> decades of life.

**CCSS** 

Entire CCSS

population

funding period

Twice in

2.

- 1. PRO-based data collection, focused on functional outcomes
- 2. Web-based neurocognitive assessment (CNS Vital Signs)

3. Develop a population resource for intervention trials through remote functional assessment of 1000 sub-cohort of survivors (frail, pre-frail, not frail)

#### Health Services Research

Given the unique healthcare needs of survivors we will enhance the resource to facilitate the conduct of health services research through collection of data to evaluate patient, provider and health care system factors and their associations with access, quality, and cost of care. Ultimately, we aim to provide a resource to identify how survivors' healthcare influences outcomes.

- FU8 Survey will assess survivors' perspectives of their unmet needs (CCSS Needs Assessment Questionnaire & Health Care Needs Study)
- Expand expertise: Claire Snyder, Ph.D.
  - Co-Chair, Cancer Control and Intervention Working Group with Paul Nathan
  - Solicit proposals for Ancillary studies



#### **Enhance Data Sharing**

To maximize access to the CCSS resource we will leverage a cloud-based sharing platform (SJ Cloud Survivorship Portal) to develop a data analysis ecosystem with tools for data access, visualization and analysis of genetic, treatment exposure and outcome data. (http://survivorship.stjude.cloud/)



#### Status:


All 25,665 participant data to be incorporated by end this year

**CCSS** 

Genotype imputation on the existing SNP array data so that they can be harmonized with the WGS samples for integrative analysis by end of this year Demo of SJ Cloud: ISLCCC, Thursday at 5:30pm !!!

## Expanding the Genomic and Biospecimen Resource: Supplemental Funding 2021

- SMN somatic tissues with matched germline specimens
  - -218 breast cancer, 116 thyroid, 111 meningioma
    -WGS, WES (Hudson Alpha), and RNAseq (St. Jude)
    -Approved concept to examine the effects of prior therapy on the genomic
    Iandscape, timing of mutation acquisition and immune infiltration signatures (Zhang)



## Expanding the Genomic and Biospecimen Resource: Supplemental Funding

	Breast	Cancer	Thyroid Cancer		Meningioma		Melanoma	
Initial Cases with Tissue in CCSS BioPathology Center	218		116		111		12	
Cases Meeting Criteria and Submitted to HudsonAlpha	127 (58%)		85 (73%)		109 (98%)		12 (%)	
	WGS	WES	WGS	WES	WGS	WES	WGS	WES
Cases Processed and had adequate nucleic acid quantity/quality from tumor tissue	90 (42%)	83 (36%)	66 (56%)	71 (63%)	71 (70%)	71 (69%)	11 (%)	3 (%)
Current Status								
In Library prep	0	0	0	0	0	0	0	0
In Sequencing	0	0	0	0	0	0	0	0
Sequencing Complete	90	82	66	71	71	71	11	3
Matched Pairs with Germline	78	76	51	65	54	57		
RNA Seq	42		49		34			

Expanding the Genomic and Biospecimen Resource: Supplemental Funding **2021** 

- 1,350 Survivors with CTCAE grade 3 and 4 chronic health conditions
  - -At high risk for mortality
  - Banking 40ml specimen as a resource for investigators, including Paxgene tube for gene expression studied
     COMPLETED!

New resource for studies of: biomarkers, gene expression, multi-omics



# STAR ACT 2022: Supplemental Funding

1. Additional support to increase (maximize) blood banking participation from 36% to >50%

- Acknowledges that in-home blood draw was performed during a pandemic
  - Re-invite participants to in-home blood draw
- Increase incentive to \$100

## 2. Additional WGS/WES of CCSS participants

- 1,750 survivors have provided a new, first-time specimen
  - saliva (2,098)
  - blood (292)
- Sequencing by Hudson Alpha
- Goal: 1,500 additional survivors with WGS/WES



## **Resource for Genetic Investigation**

Characteristic	Genotype Data Diagnosed 1970-1986 (N=5912)	Whole Exome Diagnosed 1970-1986 (N=5451)	WGS and WES Data Diagnosed 1987-1999 (N=2641)
Sex	Ν	N	Ν
Male	2781	2630	1240
Female	2958	2821	1401
Ancestry (based on genotype)			
European	5324	5105	2114
Non-European	415	346	527
Data Access	Available in dbGap	Available in dbGap	WGS Available in the St. Jude Cloud

**CCSS** 

<u>Now Available</u>: Phenotype data on all 25,665 CCSS participants in dbGap, including diagnosis, treatment and long-term outcome data

dbGaP Study Accession: phs001327.v2.p1

# STAR ACT **2023**: Supplemental Funding Application Submitted

Leverage the newly banked blood specimens to perform methylation profiling on 2,285 survivors with blood specimens

- Rationale:
  - Mechanistic insights into the increased risk of adverse outcomes among survivors of childhood cancer

- Enables the quantification of biological aging among survivors who experience accelerated aging and increased burden of aging-related morbidity and mortality
- Move us a step closer to future multi-omics integrative approach for precision survivorship research and care
- Supplement submitted, NOA pending

Strategic Plan for Future Millennium Cohort Expansion

In the future, assessment of late outcomes of novel therapies (immunotherapy, targeted/biologic, proton beam) will be essential. Thus, with NCI oversight, CCSS will formulate a strategic plan for cohort expansion.


CCSS

Begin in Funding Year 29 (Year 2 of the next award).

- Establish leadership / governance
- Convene stakeholders
- Enumerate objectives and priorities of an expansion
- Establish expertise
- Determine feasibility: define eligible population, recruitment, MRAF, identify and collect preliminary data
- Summarize assessment: infrastructure needs, feasibility, timeline, cost
- Delivery of final strategic plan report to NCI (Year 4)

## Career Development Award

#### 2023: 6 applications (2 Junior faculty, 4 trainee)



CDA: Number of Applications per Year

CCSS

■ Total ■ Junior Faculty ■ Trainee

## Career Development Award 2023

CCSS Career Development Award Winners							
Category	Awardee	Application Title	Direct Costs CCSS Work Awarded Group		Primary Mentor	Status	
2023							
Junior Faculty	Rebecca Ronsley	Prevalence of gonadal failure and infertility in survivors of childhood brain tumors	\$20,000	Chronic Disease	Eric Chow	Concept Pending Approval	
Trainee	Perri Tutelman, PhD University of Calgary	Longitudinal Patterns and Predictors of Cancer Fears in Survivors of Childhood Cancer	\$3,000	Psychology	Fiona Schulte	Concept Pending Approval	
Trainee	Chiara Papini, PhD St. Jude Children's Research Hospital	The impact of sleep trajectories on neurocognitive functioning in adult survivors of childhood cancer	\$3,000	Psychology	Tara Brinkman	Concept Pending Approval	

## Announcing the 2024 CCSS Career Development Award Application due date: October 2, 2022

See call for applications at: http://ccss.stjude.org

Designed to create an opportunity for early career investigators and trainees with an interest and aptitude in childhood cancer survivorship research to develop and complete an initial research study within the CCSS.

Leadership Transitions: CCSS Data and Statistics Center

May 1, 2023: Transition from Fred Hutch to St. Jude

Principles of the Transition:

- Kumar Srivastava leads the Center
  - Developing a statistical team in Memphis to assume data management
    - Mingjuan Wang, Senior Biostatistician + 2 new FTEs
- Wendy Leisenring has transitioned to Co-Chair Epi/Biostats Working Group
  - Pam and Kayla (Fred Hutch) will continue with same level of support from CCSS



## Leadership Transitions: CCSS Coordinating Center

February, 2023: Aaron McDonald, PhD

- Promoted to Director of Research, Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital

New CCSS Project Director (July 17, 2023): Vikki Nolan, PhD

- PhD in Epidemiology, Boston University
  - MPH, Yale
- Assoc. Dean for Academic Affairs, University of Memphis
- 2008: CCSS/SJLIFE data analyst





# You are formally invited to attend the CCSS Founders Reception

## Tonight!

6:30 - 7:30 pm Garden Courtyard

# Steering Committee: Initial Members

Les Robison John D. Boice Norman E. Breslow Sarah S. Donaldson Dan Green Frederic P. Li Anna T. Meadows Ann Mertens John Mulvihill Joe Neglia



Mark E. Nesbit Roger J. Packer John D. Potter Charles A. Sklar Malcolm A. Smith Marilyn Stovall Louise C. Strong Yutaka Yasui Lonnie K. Zeltzer

# Initial Institutional Principal Investigators

Arthur Ablin **Roger Berkow** George Buchanan **Zoann Dreyer Daniel Green** Mark Greenberg Holcombe Grier Melissa Hudson **Raymond Hutchinson** Michael Link Anna Meadows Joe Neglia Lorie Odom

Maura O'Leary **Thomas Pendergrass Gregory Reaman Kim Ritchey** Kathy Ruccione **Frederick Ruymann Charles Sklar** Anthony Smithson Louise Strong **Robert Weetman** Teresa Vietti Lonnie Zeltzer

## Team Science: Thank You!

#### Working Group Chairs

Smita Bhatia, University of Alabama at Birmingham Eric Chow, Fred Hutchinson Cancer Center Kevin Krull, St. Jude Children's Research Hospital Paul Nathan, Toronto Hospital for Sick Children Joe Neglia, University of Minnesota Kevin Oeffinger, Duke University Claire Snyder, Johns Hopkins University Lucie Turcotte, University of Minnesota Yutaka Yasui, St. Jude Children's Research Hospital

#### Support Facility Leaders

Aaron McDonald, St Jude Children's Research Hospital Michael Arnold, Children's Hospital Colorado Stella Davies, Cincinnati Children's Hospital Rebecca Howell, MD Anderson Cancer Center Wendy Leisenring, Fred Hutchinson Cancer Center

#### **Executive Committee**

Saro Armenian, City of Hope Smita Bhatia, University of Alabama at Birmingham Eric Chow, Fred Hutchinson Cancer Center Dan Green, St. Jude Children's Research Hospital Rebecca Howell, MD Anderson Cancer Center Melissa Hudson, St. Jude Children's Research Hospital Kevin Krull, St. Jude Children's Research Hospital Wendy Leisenring, Fred Hutchinson Cancer Center Paul Nathan, Toronto Hospital for Sick Children Joseph Neglia, University of Minnesota Kiri Ness, St. Jude Children's Research Hospital Kevin Oeffinger, Duke University Les Robison, St. Jude Children's Research Hospital Nita Seibel, National Cancer Institute Charles Sklar, Memorial Sloan Kettering Cancer Center Claire Snyder, Johns Hopkins University Lucie Turcotte, University of Minnesota Yutaka Yasui, St. Jude Children's Research Hospital

#### **Publications Committee**

Saro Armenian, City of Hope James Bates, Emory University Kim Edelstein, Princess Margaret Cancer Center Monica Gramatges, Texas Children's Hospital Rebecca Howell, MD Anderson Cancer Center Anne Kirchhoff, University of Utah Wendy Leisenring, Fred Hutchinson Cancer Center Aaron McDonald, St. Jude Children's Research Hospital Chaya Moskowitz, Memorial Sloan Kettering Cancer Center Goli Mostoufi-Moab, Children's Hospital of Philadelphia Kiri Ness, St. Jude Children's Research Hospital Yadav Sapkota, St. Jude Children's Research Hospital Noha Sharafeldin, University of Alabama at Birmingham Lucie Turcotte, University of Minnesota Ellen van der Plas, University of Arkansas Medical School Lynda Vrooman, Dana-Farber Cancer Institute Zhaoming Wang, St. Jude Children's Research Hospital Suzanne Wolden, Memorial Sloan Kettering Cancer Center

#### Steering Committee

John Boice, Vanderbilt University Sandy Constine, University of Rochester Lisa Diller, Dana-Farber Cancer Institute Sarah Donaldson, Stanford University Lori Henderson, National Cancer Institute Ann Mertens, Emory University Lindsay Morton, National Cancer Institute Louise Strong, MD Anderson Cancer Center Chris Weldon, Boston Children's Hospital Lonnie Zeltzer, UCLA

#### St Jude Faculty and Staff

Shani Alston Harmony Farner Nita Anderson Jessica Flynn Abbe Anderson Tracie Gatewood Jessica Baedke Tolly Gillenwaters Theresa Bailey Haley Harlan Netha Banks Geehong Hyun Ollie Battle Lisa Jacola Yaniz Booth Elizabeth Johnson Tara Brinkman Patricia Key Andrew Cobble Margie King Christie Cooper Komal Kochar Tabitha Cross Jennifer Lanctot Sheila Crutcher Kathy Laub Shannon Dodds Michael LaVoice Ricardo Duran Trinity LaVoice John Easton Carol Lee Matthew Ehrhardt Kisten Lenoir Lacy Ellis Barbara Lewis

#### **Education Committee**

Catherine Coleman, Harvard University Kayla Foster, Texas Children's Hospital Melissa Hudson, St. Jude Children's Research Hospital Carol Lowenstein, Harvard University Aaron McDonald, St. Jude Children's Research Hospital Diana Merino, All Stripes Kathy Ruccione, Azusa Pacific University Julia Stepenske, Advocate Children's Hospital

#### Institutional Principal Investigators

Saro Armenian	Jennifer Dean	Jill Ginsberg	Ray Hutchinson	Denise Rokitka	Kimberly Whelan
Carola Arndt	Lisa Diller	Rob Goldsby	Katherine Rae Lange	Karim Sadek	
Scott Baker	ZoAnn Dreyer	Tanja Gruber	Paul Nathan	Jenna Sopfe	
Donald Beam	Karen Effinger	Robert Hayashi	Lilibeth Torno	Louise Strong	
Dan Bowers	David Freyer	Tara Henderson	Randy Olshefski	Jean Tersak	
Jackie Casillas	Danielle Friedman	Melissa Hudson	Jennifer Reicheck	Jean Tersak Terry Vik	

#### CCSS

Kumar Srivastava Zhenghong Li Rachel Tillery Janna Lipford Ramona Veiandla John Lucas Chris Vukadinovich Telisa McKinney Aimee Montgomerv Mingjuan Wang Wonjong Moon Sharon Walker Daniel Mulrooney Stacy Wallace Lauren Williams Brent Orr Robyn Partin Nicole Wilson Casev Mastio-Partridge Carmen Wilson Avnisha Patel Porsceh Wright Nick Phillips Jinghui Zhang Sean Phipps Suyena Poudel Dayton Rinehart Sedigheh Mirzai Salehabadi Tishana Sharp Jin-ah Sim

#### External Advisors

Garnet Anderson, Fred Hutchinson Cancer Center Melissa Bondy, Baylor College of Medicine Susan Cohn, University of Chicago David Hodgson, University of Toronto Timothy Rebbeck, Harvard University Flora Van Leeuwen, Netherlands Cancer Institute Susan Weiner, Children's Cause for Cancer Advocacy